Katama Pharmaceuticals Inc.
Resurrecting a muscle relaxant for acute back pain
This article was originally published in Start Up
Katama Pharmaceuticals Inc. was built around tolperisone, a generic, oral small molecule muscle relaxant manufactured and sold in Europe for the treatment of muscular pain and neuromuscular spasms. Katama aims to launch its version in the US, initially for treating acute lower back pain.
You may also be interested in...
Pain Drug Development Becomes Personalized
Advances in pain neurobiology point to the promise of more specific drugs with fewer side effects, yet the field continues to show few successes. Nevertheless, fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers.
Personalized Pain Drug Development
Fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers. We profile three new entrants in this issue: Adynxx, Afferent Pharmaceuticals, and Katama Pharmaceuticals.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.